health
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.
TL;DR
- Bristol Myers Squibb and Hengrui Pharma are entering a multibillion-dollar partnership for drug development and discovery.
- The deal involves Bristol sending several experimental drugs to China for Hengrui to conduct early-stage clinical trials.
- This partnership is seen as more reciprocal than previous collaborations between U.S. and Chinese drugmakers.
- U.S. and European pharmaceutical companies are increasingly licensing deals from China, with a significant rise in recent years.
- Experts believe China is becoming an integral part of the global pharmaceutical research and development system.
- The trend suggests early-stage drug discovery may increasingly shift to China due to efficiency and cost benefits.
- While mid- and late-stage trials will likely remain in the U.S., early studies in China could accelerate drug launches.
- There are differing views on whether China's growing role benefits or harms the U.S. biopharmaceutical industry, but its influence is undeniable.